TICKERNERD
Menu
SYKSYKHealthcare · Medical Devices

SYK Stock Forecast: Stryker Corp. Price Predictions for 2026-2027

Last close, 3 Sept 2026
$308
−1.35% on the day

The 28 Wall Street analysts covering Stryker Corp. hold a median 12-month price target of $382 — +24.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 2 Sept 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$119.7B
Ticker Nerd rank
74 / 100
Median analyst target
$382
Analysts covering
28
Revenue$6.6B+9.4% y/y
Operating income$1.7B
Net income$1.3B
Free cash flow$1.1B
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.4%
1M
−9.7%
YTD
−11.9%
1Y
−19.9%
From 52W high
−21.1%
From 52W low
+9.3%
$282
$390
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SYK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Stryker Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 2 Sept 2026
74 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
99
Issuance
87
Quality
86
Value
82
Growth
72
Accruals
58
Revisions
53
Momentum
34
Size
2

Volatility (99): The share price has been relatively steady.

Momentum (34): The shares have been drifting down relative to others.

Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SYK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SYK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$300$350$400$450Oct 25Jan 26Apr 26Jul 26SYKHigh $465Median $382Low $315

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says28 analysts
22 Buy6 Hold0 Sell
Low $315Median $382High $465

The green dot is the last close — the median target sits +24.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 6 moved it down.

DateFirmActionRatingTarget
13 Aug 2026Wolfe ResearchDowngradePeer Perform—
3 Aug 2026CitizensMaintainsMarket Outperform$440 → $400
3 Aug 2026CitizensMaintainsMarket Outperform—
31 July 2026BTIGMaintainsBuy$371 → $358
31 July 2026BTIGMaintainsBuy—
31 July 2026JP MorganMaintainsOverweight$400 → $350
31 July 2026JP MorganMaintainsOverweight—
31 July 2026Piper SandlerMaintainsOverweight—
31 July 2026Piper SandlerMaintainsOverweight$420 → $390
31 July 2026RBC CapitalMaintainsOutperform—
31 July 2026RBC CapitalMaintainsOutperform$435 → $420
31 July 2026Truist SecuritiesMaintainsHold$330 → $340
31 July 2026Truist SecuritiesMaintainsHold—
28 July 2026UBSAssumesBuy$400
9 July 2026BMO CapitalInitiatesOutperform—
6 July 2026Evercore ISI GroupMaintainsOutperform$355 → $350
6 July 2026Evercore ISI GroupMaintainsOutperform—
5 June 2026Leerink PartnersMaintainsOutperform—
4 May 2026BarclaysMaintainsOverweight—
4 May 2026Truist SecuritiesReiteratesHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SYK appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SYK vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 3 Sept 2026, Stryker Corp. returned −19.9% against +21.4% for the S&P 500, dividends included.

SYK vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Oct 25Jan 26Apr 26Jul 26SYKS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SYK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.2%
Analysts raising
17
Analysts cutting
3
Fundamentals

Stryker Corp. (SYK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
32.4×

Cheaper than 24% of US stocks

Price / sales
4.6×

Cheaper than 27% of US stocks

Price / book
5.0×

Cheaper than 21% of US stocks

EV / EBITDA
17.9×

Cheaper than 18% of US stocks

Growth & margins
Revenue growth (YoY)
9.4%

Higher than 50% of US stocks

Earnings growth (YoY)
44.3%

Higher than 73% of US stocks

Gross margin
68.3%

Higher than 81% of US stocks

Operating margin
27.0%

Higher than 85% of US stocks

Net margin
14.4%

Higher than 77% of US stocks

Returns & dividend
Return on equity
16.5%

Higher than 77% of US stocks

Return on assets
8.2%

Higher than 88% of US stocks

Dividend yield
1.1%

Higher than 26% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Stryker Corp. (SYK) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Stryker Corp. has a market value of $119.7B and an enterprise value of $131.7B.

  • Revenue in the twelve months to 30 June 2026: $25.8B. The latest quarter grew 9.4% year on year.

  • Net income over the same four quarters: $3.7B, a 14.4% net margin.

  • Diluted earnings per share, trailing twelve months: $9.65.

  • Free cash flow in the twelve months to 30 June 2026: $4.7B.

  • Stryker Corp. spent $1.3B on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 383.6M.

  • Trailing P/E: 32.4×; forward P/E: 18.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 1.13%, paying out 36% of earnings.

  • Stryker Corp. employs 56,000 people — $461K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 3 Sept 2026

Data provided by Twelve Data

Peers

SYK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
SYKStryker Corp.$119.7B
74
MDTMedtronic PLC$118.2B
82
ABTAbbott Laboratories$192.1B
55
BSXBoston Scientific Corp.$71.7B
58
EWEdwards Lifesciences Corp.$52.3B
90
DXCMDexCom, Inc.$34.6B
99
GEHCGE Healthcare Technologies, Inc.$32.1B
65

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Stryker Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SYK news & analysis

Stryker Launches FDA-Cleared Apple Vision Pro Surgical App

Zacks Investment Research · 3 Sept 2026positive

Stryker has launched SportSuite Vision, an FDA-cleared surgical app that brings Apple Vision Pro into hip arthroscopy procedures. The move strengthens Stryker's digital surgery efforts and its Sports Medicine portfolio.

Why it matters — This FDA-cleared integration of Apple Vision Pro into hip arthroscopy signals Stryker's continued expansion in digital surgery and its Sports Medicine segment.

Stryker to Acquire ZuriMED to Expand Its Shoulder Care Portfolio

Zacks Investment Research · 1 Sept 2026positive

Stryker Corp. plans to acquire ZuriMED, adding the FiberLocker System to its product lineup. The acquisition is intended to strengthen Stryker's shoulder portfolio and rotator cuff care capabilities.

Why it matters — This acquisition could expand Stryker's presence in shoulder care and rotator cuff procedures, broadening its musculoskeletal product offerings.

Stryker introduces first of its kind FDA-authorized surgical application for Apple Vision Pro with hip arthroscopy case at nationally recognized academic medical center

PRNewsWire · 1 Sept 2026positive

Stryker announced it received FDA De Novo authorization for SportSuite Vision, the first surgical application for intraoperative use with Apple Vision Pro, and successfully completed the first hip arthroscopy procedure using the technology at a leading academic medical center.

Why it matters — The regulatory approval and successful clinical use of SportSuite Vision position Stryker at the forefront of bringing spatial computing into the operating room, expanding its surgical technology portfolio.

Stryker signs definitive agreement to acquire ZuriMED to enhance its shoulder offering

GlobeNewsWire · 31 Aug 2026positive

Stryker announced it has signed a definitive agreement to acquire ZuriMED, a privately held company that developed the commercialized FiberLocker System for rotator cuff augmentation. The technology provides increased biomechanical strength to address a key clinical failure mode in rotator cuff repair.

Why it matters — SYK watchers would care because the acquisition adds a novel shoulder-technology offering that could strengthen Stryker's medical-technologies portfolio.

PBH vs. SYK: Which Stock Is the Better Value Option?

Zacks Investment Research · 28 Aug 2026neutral

Zacks Investment Research published an article posing a value-investing comparison between Prestige Consumer Healthcare (PBH) and Stryker (SYK), both of which it identifies as stocks in the Medical - Products space. The piece asks which of the two currently offers value investors the better option, without stating a conclusion in the excerpt.

Why it matters — The item frames Stryker's stock in a value-investing context, giving SKY watchers a direct valuation comparison against a peer.

FAQ

Frequently asked questions about SYK stock

What is the SYK stock price forecast for 2026-2027?

The 28 Wall Street analysts covering Stryker Corp. have a median 12-month price target of $382, with estimates ranging from $315 to $465. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SYK stock a buy right now?

Of the 28 analysts covering Stryker Corp., 22 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Stryker Corp. 74 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SYK?

As at 2 Sept 2026, Stryker Corp. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).

Will SYK stock go up?

No one can know that. What the data says: the median 12-month target from 28 analysts implies +24.0% from the last close, and Ticker Nerd's factor model ranks Stryker Corp. 74 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SYK stock forecast for 2030?

No analyst covering Stryker Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SYK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $315 to $465 over the next 12 months.

How has SYK stock performed over the past year?

Stryker Corp. returned -19.9% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Stryker Corp. do?

Stryker Corp. is a medical technology company focused on products and services that support patient care and healthcare delivery.

What is the latest news on SYK?

The most recent item we track (Zacks Investment Research, 3 Sept 2026): "Stryker Launches FDA-Cleared Apple Vision Pro Surgical App". Stryker has launched SportSuite Vision, an FDA-cleared surgical app that brings Apple Vision Pro into hip arthroscopy procedures. The move strengthens Stryker's digital surgery efforts and its Sports Medicine portfolio.

Company

About Stryker Corp.

Stryker Corp. is a medical technology company focused on products and services that support patient care and healthcare delivery. The company operates across MedSurg, Neurotechnology, and Orthopaedics, supplying hospitals, surgeons, and other healthcare providers with surgical equipment, endoscopic and communications systems, patient handling tools, emergency medical equipment, implantable devices, and neurovascular solutions. Its orthopaedics business includes implants used in joint replacement, trauma, and extremities procedures, while its medical and surgical portfolio addresses operating room efficiency, clinical workflows, and perioperative care. Stryker Corp. plays an important role in the global healthcare market by providing technologies that are used in surgery, acute care, and orthopedic treatment across a wide range of clinical settings.

CEO Mr. Kevin A. Lobo · 56,000 employees · United States · https://www.stryker.com